• When CDK4/6 Blockade Fuels PDAC Invasion

  2026-10-15

  Gu et al. report that palbociclib suppressed pancreatic ductal adenocarcinoma growth but simultaneously increased migration, invasion, and epithelial-to-mesenchymal transition through a GSK3β–Wnt/β-catenin-associated mechanism. Their preclinical data suggest that BET inhibition with JQ1 counteracted these effects, although the findings remain limited by model scope, incomplete quantitative reporting in the available excerpt, and the absence of clinical validation. GDC-0941 is a mechanistically adjacent PI3K inhibitor, but it was not tested in the cited study and should not be presented as evidence for the reported CDK4/6–BET combination.

• Protoporphyrin IX: Identity, Mechanism and Evidence

  2026-10-15

  A source-bounded overview of Protoporphyrin IX as a heme-biosynthetic intermediate and photodynamic compound. The available product information supports chemical identity, pathway context, and broad application claims, but provides no product-matched study outcomes, effect sizes, or evidence of clinical or experimental performance.

• X-press Tag Peptide: Evidence and Scope

  2026-10-14

  APExBIO describes X-press Tag Peptide (A6010) as an N-terminal leader peptide combining a polyhistidine sequence, an Xpress epitope from bacteriophage T7 gene 10 protein, and an enterokinase cleavage site. Its documented rationale is to support affinity capture with ProBond resin and Anti-Xpress antibody detection in recombinant protein workflows. However, the available evidence is product documentation rather than an identity-matched research study, so functional performance, recovery, specificity, cleavage efficiency, and comparative advantages remain unestablished.

• Acifran and the Structural Biology of HCAR Selectivity

  2026-10-14

  A source-grounded overview of what recent cryo-EM work reports about Acifran at HCAR2 and HCAR3, with emphasis on receptor recognition, lipid signaling interpretation, and the limits of translating structural observations into pharmacological or clinical conclusions.

• Mitomycin C: Evidence Boundaries in Cancer Research

  2026-10-13

  The supplied materials describe Mitomycin C as an antitumor antibiotic with reported DNA-directed cytotoxicity and apoptosis-related activity, while the cited SCUBE3 study evaluates a separate antibody-based strategy. The evidence does not establish a mechanistic or therapeutic connection between Mitomycin C and SCUBE3.

• FAM46C as a Brake on Plk4-Driven Tumor Biology

  2026-10-13

  A source-grounded overview of how Kazazian and colleagues connect FAM46C/TENT5C to Plk4 regulation, centriole control, cancer-cell invasion, xenograft growth and colorectal tumor pathology, while separating reported findings from broader interpretation.

• Protoporphyrin IX and Ferroptosis: Evidence Boundaries

  2026-10-12

  Protoporphyrin IX connects heme formation, iron biology and photodynamic chemistry, but the supplied hepatocellular carcinoma study does not establish it as a ferroptosis modulator or therapeutic intervention. Wang et al. instead identify a METTL16–SENP3–LTF axis that influences labile iron and ferroptosis resistance in preclinical HCC models.

• Purmorphamine and Smoothened: Evidence Gaps

  2026-10-12

  A source-grounded assessment of a honeybee Smoothened comparison, distinguishing reported pharmacological effects from causal interpretation and from supplier claims about osteogenic and related research applications.

• Vitamin C and HEV Organoid Evidence

  2026-10-11

  The cited 2025 Gut study shows that iPSC-derived liver, intestinal and brain organoids can model infection by HEV genotypes 1, 3 and 4, including tissue-specific injury and partial reversal with ribavirin. It does not evaluate Vitamin C or ascorbic acid, so anticancer findings from separate product materials cannot be interpreted as evidence of anti-HEV activity.

• Rosiglitazone and Beige Fat: Reading the Evidence

  2026-10-10

  Rosiglitazone, also known as Brl-49653, is a powerful lens for studying PPARγ biology, but beige-fat research requires careful separation of direct evidence from mechanistic analogy. This article examines how the SEMA3E–β-catenin findings refine interpretation of adipogenesis, thermogenesis, and insulin sensitivity research.

• SR 11302 and AP-1: Evidence in Cancer Research

  2026-10-09

  SR 11302 is presented as a non-retinoid AP-1 transcription factor inhibitor with reported activity in selected cancer-cell and papilloma models. This overview separates supplier-reported findings from peer-reviewed evidence, including a 2024 colitis-associated colorectal cancer study that used SR 11302 among pathway antagonists but did not directly establish it as the study’s primary intervention.

• METTL16–SENP3–LTF Axis in HCC Ferroptosis

  2026-10-09

  Wang et al. identify a METTL16–SENP3–LTF signaling axis that links m6A-dependent RNA regulation to iron handling and ferroptosis resistance in hepatocellular carcinoma. Across cellular, organoid, animal, and human-sample evidence, the study suggests that this pathway may influence tumor progression, while its translational relevance remains limited by model dependence and the absence of clinical intervention data.

• X-press Tag Peptide in Neddylation Research

  2026-10-08

  This overview places the X-press Tag Peptide in the broader context of recombinant protein purification and examines how tagged-protein approaches may conceptually support research into RHEB neddylation, mTORC1 signaling and liver tumorigenesis. It separates supplier-reported product features from findings reported by Zhang et al. and identifies important evidence and applicability limits.

• OTUD7B, p62, and IRF3 in Antiviral Immunity

  2026-10-08

  The reference study identifies OTUD7B as a negative regulator of antiviral signaling that links SQSTM1/p62 deubiquitination to selective autophagic degradation of IRF3. Its main contribution is a mechanistic model in which OTUD7B removes K63-linked ubiquitin chains from p62 at K7, promotes p62 oligomerization, and establishes feedback that limits type I interferon signaling.

• FLAG Tag Peptide in Translational Protein Science

  2026-10-07

  A source-grounded analysis of how the DYKDDDDK peptide supports protein-complex purification, recombinant protein detection, and translational assay strategy, using recent Mediator-complex research to define both its value and its boundaries.

8108 records 1/541 page Next 12345 下5页 Last page